CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an inve...
Q1 2026
May 8, 2026
FY 2025
Feb 27, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 8, 2025